NATCO Pharma Limited

NATCOPHARM

INE987B01026

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 00:21:10 2024-05-29 EDT			5-day change	1st Jan Change
1,057 ^INR	+2.39%		+5.37%	+30.27%

05-28	INDIA STOCKS-Metal, pharma stocks drive Indian benchmarks higher	RE
05-28	Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024

Natco Pharma Limited Approves Re-Designation of Mr. Rajeev Nannapaneni as Vice Chairman & CEO

May 28, 2012 at 11:52 pm

Natco Pharma Limited at its Board of meeting held on May 28, 2012, approved the re-designation of Mr. Rajeev Nannapaneni as Vice Chairman & CEO.

Latest news about NATCO Pharma Limited

INDIA STOCKS-Metal, pharma stocks drive Indian benchmarks higher	05-28	RE
Transcript : NATCO Pharma Limited, Q4 2024 Earnings Call, May 28, 2024	05-28
NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-27	CI
NATCO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-27	CI
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	05-08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	05-08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	05-08	MT
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	04-09	MT
NATCO Pharma Limited Announces Board Appointments	03-27	CI
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks	02-18	RE
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	02-15	CI
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024	02-15
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	02-14	CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited	01-16	CI
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India	12-07	MT
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023	11-15
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	11-14	MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	11-14	CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	11-02	MT
Transcript : NATCO Pharma Limited - Shareholder/Analyst Call	23-09-29
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited	23-09-11	CI
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises	23-09-08	MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	23-09-08	MT

Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.

Sector

Pharmaceuticals

Calendar

01:30am - Investor Meeting - ICICI Securities

More about the company

Income Statement Evolution

More financial data

Ratings for NATCO Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,032 INR

Average target price

988.1 INR

Spread / Average Target

-4.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NATCO PHARMA LIMITED	+30.27%	2.22B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B

Other Pharmaceuticals